| CGON |
CG Oncology, Inc. |
72%
|
rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our product revenues, if any, may be lower t… |
| CGON |
CG Oncology, Inc. |
72%
|
Reciprocal relationship from CGON graph: Reciprocal relationship from AURA graph: rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to … |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from AURA graph: rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to p… |
| JNJ |
Johnson & Johnson |
72%
|
rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our product revenues, if any, may be lower t… |
| URGN |
UroGen Pharma Ltd. |
72%
|
Reciprocal relationship from URGN graph: Reciprocal relationship from AURA graph: rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to … |
| URGN |
UroGen Pharma Ltd. |
72%
|
rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our product revenues, if any, may be lower t… |
| CLEARSIDE-BIOMEDICAL-INC |
CLEARSIDE-BIOMEDICAL-INC |
62%
|
valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek comm… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
lity to commercialize any current or future product candidates that we may develop. While we maintain product liability insurance, we anticipate that we will need to increase our insurance coverage a… |
| EMERGING-GROWTH-COMPANY |
EMERGING-GROWTH-COMPANY |
62%
|
third-party and government payors; ▪ the effect of competing technological and market developments; ▪ the extent to which we acquire or invest in businesses, products, and technologies; and ▪ unfavor… |
| JOHNSON-UROGEN-PHARMA-LTD-CG-ONCOLOGY-INC-IMMUNI |
JOHNSON-UROGEN-PHARMA-LTD-CG-ONCOLOGY-INC-IMMUNI |
62%
|
rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our product revenues, if any, may be lower t… |
